Last year, a group lobbying for government funds to develop better ways to detect prostate cancer launched a public awareness program with an iconic spokesgland. Prosty’s lighthearted delivery of a no-nonsense message about prostate cancer appears to be paying off.
Last year, a group lobbying for government funds to develop better ways to detect prostate cancer launched a public awareness program with an iconic spokesgland. Prosty's lighthearted delivery of a no-nonsense message about prostate cancer appears to be paying off.
The AdMeTech Foundation, which developed the campaign, announced last week that 43 members of the U.S. House of Representatives have cosigned a bipartisan bill, HR 863, that calls for increased attention to and investment in prostate imaging and image-guided minimally invasive treatment for prostate cancer.
The foundation developed and championed this resolution in cooperation with Rep. Elijah Cummings (D-MD), a senior member of Congress and former chair of the Congressional Black Caucus.
The resolution "expresses the sense of the House of Representatives" that there should be an increased federal commitment to supporting the development of innovative advanced imaging technologies for prostate cancer detection and treatment, according to the legislation. HR 863 notes that prostate cancer has reached epidemic proportions, striking at least one in six men in the U.S., with African Americans having a 60% higher incidence than whites and a mortality rate twice as high.
The resolution calls for Congress and the executive branch to provide additional support for the research and development of technologies for prostate cancer detection and treatment comparable to state-of-the-art mammograms.
For further information from the Diagnostic Imaging archives:
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.